MetaVia presents obesity drug data showing 9.1% weight loss at ADA 2026
MetaVia announced Phase 1 results for DA-1726 showing up to 9.1% mean body weight reduction and preclinical data supporting combination therapies for metabolic diseases. The data demonstrates potential differentiation of the company's cardiometabolic pipeline and supports advancement toward higher-dose studies.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day